InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
5,983.44
(
0.17%
)
US TECH 100
20,552.40
(
0.05%
)
Dow Jones
43,856.16
(
0.29%
)
Brent Oil
74.11
(
-1.80%
)
Bitcoin
75,747.54
(
-0.19%
)
Post# of 253552
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next

microcapfun

Send PM Follow Ignore
Followers 7
Posts 560
Boards Moderated 0
Alias Born 03/13/2007

microcapfun

Re: None

Wednesday, 11/25/2009 1:45:33 AM

Wednesday, November 25, 2009 1:45:33 AM

Post# of 253552
Incyte

http://investor.incyte.com/phoenix.zhtml?c=69764&p=irol-newsArticle&ID=1359169&highlight=

This looks like a truly excellent partnership deal for Incyte. I've never seen such a good deal for a product which isn't through Phase 3 (plus a preclinical candidate thrown in). Note that Incyte is keeping all U.S. rights, all non-oncology/hematology rights (e.g. RA) and may get a total of $1.31B in upfront payment and milestones. Plus Novartis pays much of the future development costs and gives Incyte a double digit royalty on ex-U.S. sales. Pretty amazing.

It seems clear that Novartis thinks the hem-onc JAK2 inhibitor market is likely to be a lot bigger than just myelofibrosis ...

micro

Life is an IQ test.

email: microcapfun@yahoo.com

Public Reply Private Reply New Post
Keep Last Read
Replies (2) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (2) Next 10 Prev Next
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up